Active	Status	Sponsor type	Region	Phase	Filter
7 Active 5 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vries, Elisabeth GE de
CBT307-1, NCT05836623: A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions	Active, not recruiting	1	5	Europe	Radiolabelled CB307, 89Zr-CB307, CB307	Crescendo Biologics Ltd., University Medical Center Groningen	Advanced and/or Metastatic Solid Tumours	01/24	10/24
POTENTIA, NCT04839991: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.	Recruiting	1	70	Europe, US	CB307	Crescendo Biologics Ltd.	Advanced and/or Metastatic Solid Tumours	07/24	09/24
NCT03850028 / 2017-003511-20: Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients	Withdrawn	N/A	20	Europe	89Zr-atezolizumab PET scans	University Medical Center Groningen, Amsterdam UMC, location VUmc, Stichting Hemato-Oncologie voor Volwassenen Nederland, Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	05/22	05/22
Tilson, Julia
CBT307-1, NCT05836623: A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions	Active, not recruiting	1	5	Europe	Radiolabelled CB307, 89Zr-CB307, CB307	Crescendo Biologics Ltd., University Medical Center Groningen	Advanced and/or Metastatic Solid Tumours	01/24	10/24